0000874015-17-000050.txt : 20170718 0000874015-17-000050.hdr.sgml : 20170718 20170718190111 ACCESSION NUMBER: 0000874015-17-000050 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170717 FILED AS OF DATE: 20170718 DATE AS OF CHANGE: 20170718 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CROOKE STANLEY T CENTRAL INDEX KEY: 0000897667 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 17970384 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2017-07-17 0000874015 IONIS PHARMACEUTICALS INC IONS 0000897667 CROOKE STANLEY T C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT CARLSBAD CA 92010 1 1 0 0 Chairman and CEO Common Stock 2017-07-17 2017-07-17 4 M 0 15000 14.69 A 53014 D Common Stock 2017-07-17 2017-07-17 4 S 0 15000 52.45 D 38014 D Common Stock 2017-07-17 2017-07-17 4 M 0 1500 7.25 A 4562 I By wife Common Stock 2017-07-17 2017-07-17 4 S 0 1500 52.45 D 3062 I By wife Common Stock 725391 I By trust Employee Stock Option (right to buy) 14.69 2017-07-17 2017-07-17 4 M 0 15000 0 D 2017-01-02 2020-01-29 Common Stock 15000 116642 D Employee Stock Option (right to buy) 7.25 2017-07-17 2017-07-17 4 M 0 1500 0 D 2016-01-03 2019-01-02 Common Stock 1500 5904 I By wife Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.35 to $52.50, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's on 9/21/2015 and 6/17/2016. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.35 to $52.50, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. /s/Stanley T. Crooke 2017-07-18